Cftr Trikafta denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Step-Therapy to Trikafta

Step-therapy (also called "fail-first") protocols require patients to try and demonstrate failure of one or more lower-cost alternatives before the plan will cover the requested drug. For CFTR modulator combination therapies, step-therapy requirements are sometimes applied — but their clinical appropriateness depends heavily on the patient's confirmed CFTR genotype, because not all modulator therapies are approved or effective across all mutation profiles. A step-therapy denial is often overturned when the appeal documents either (1) that the required step-therapy alternatives are not FDA-approved for this patient's specific genotype, or (2) that the required alternatives were already tried with documented failure or intolerance.

Many states also have step-therapy override laws that require plans to honor step-therapy exceptions when a clinician documents that the required prior therapy is contraindicated, likely to cause harm, or previously tried and failed. Check your state insurance commissioner's website for applicable protections.

## Your Federal Appeal Rights

Under ACA §2719 and ERISA §503, step-therapy denials are subject to full internal and external appeal rights. You have 180 days from the denial to file an internal appeal and typically four months after an internal denial to request independent external review. Expedited review is available for urgent clinical situations.

## The Concrete Appeal Process

1. Identify the exact alternatives BCBS requires — the denial letter or coverage policy must specify. 2. Determine whether those alternatives are FDA-approved for this patient's CFTR genotype — if not, document this as the primary rebuttal. 3. Document any prior trials of required alternatives, with dates, doses, outcomes, and reason for discontinuation. 4. File a written internal appeal with the prescriber's step-therapy exception letter and supporting chart documentation. 5. If denied, request independent external review and, if applicable, file a step-therapy override request under your state's law.

## Documentation to Gather

• Confirmed CFTR genotype report — essential for arguing genotype-specific indication mismatch with required step alternatives
• FDA prescribing labels for both the requested drug and any required step alternatives, showing approved indications
• Prior therapy records with dates, responses, and documented failure or intolerance (if alternatives were tried)
• Prescriber's step-therapy exception letter citing clinical rationale, applicable CF Foundation guidelines, and genotype-specific indication data
• State step-therapy override law citation, if applicable in your state

## Criteria-Mapping Structure

Obtain BCBS's step-therapy protocol for this drug. Then respond to each step requirement:

| Step Requirement | Patient Status / Rebuttal | |---|---| | Required prior therapy #1 | FDA-approved for this genotype? Prior trial documented? | | Required prior therapy #2 (if any) | Same analysis | | Clinical exception criteria | Prescriber attestation + chart evidence | | State override law applicability | Cite statute if applicable |

Genotype-specificity arguments are particularly powerful here: if the plan's required step alternatives are not indicated for this patient's mutation profile, step-therapy cannot ethically or legally require trial of a non-indicated drug.